|
Active substance |
ocrelizumab |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
Primary progressive multiple sclerosis. |
|
Public documents |
|
|
Last update |
08/01/2019 |
Ocrevus®
Last updated on 10/09/2024